THE LONG-TERM SEROLOGICAL PROFILE OF CORONAVAC VACCINE BASED ON COMORBIDITIES AND HISTORY OF SARS-COV-2 INFECTION IN INDONESIA.

CoronaVac emerged as one of the most widely administered COVID-19 vaccine in Indonesia. Previous research has documented various figures regarding its effectiveness in protecting against COVID-19 in several countries. Therefore, this research aims to assess the long-term immunogenicity profile in individuals with comorbidities or history of SARS-CoV-2 infection. The level of total anti-N Ig and anti-S-RBD Ig at 7 weeks and 26 weeks after receiving the second dose was observed in 194 health workers. The participants were divided into groups based on their comorbidities and history of SARS-CoV-2 infection. The results showed that there was no difference in both antibody titers between healthy and comorbid groups without any history of SARS-CoV-2 infection. The level of total anti-nucleocapsid Ig was significantly lower compared to the infected groups, and similar results were obtained in the total anti-S-RBD Ig level. Based on the results, CoronaVac induced a lower specific antibodies response compared to natural infection and also reduced immunogenicity in the long term.